Cel­gene forges can­cer pact with CRT; FDA OKs Pfiz­er's Xel­janz as treat­ment for pso­ri­at­ic arthri­tis

→ Cel­gene has signed a five-year deal with Can­cer Re­search UK’s sub­sidiary Can­cer Re­search Tech­nol­o­gy to dis­cov­er, de­vel­op, and com­mer­cial­ize on­col­o­gy drugs. The duo will …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER